Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis
Purpose: Recently, the U.S. Food and Drug Administration (FDA) approved stiripentol, cannabidiol, and fenfluramine to treat patients with Dravet syndrome (DS). Moreover, soticlestat was determined as a promising new drug for the treatment of DS as it has good efficacy and safety. However, the effica...
Saved in:
Main Authors: | Jianhua Wu (Author), Liu Zhang (Author), Xi Zhou (Author), Jiajun Wang (Author), Xiangyi Zheng (Author), Hankun Hu (Author), Dongfang Wu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acute effect of antiseizure drugs on background oscillations in Scn1aA1783V Dravet syndrome mouse model
by: Shir Quinn, et al.
Published: (2023) -
Efficacy and safety of fenfluramine in the treatment of Dravet syndrome - literature review
by: Martyna Stefaniak, et al.
Published: (2022) -
Comparative antiseizure medications of adjunctive treatment for children with drug-resistant focal-onset seizures: A systematic review and network meta-analysis
by: Lanlan Zhang, et al.
Published: (2022) -
Dravet syndrome
by: Incorpora Gemma
Published: (2009) -
Population pharmacokinetics of intravenous daptomycin in critically ill patients: implications for selection of dosage regimens
by: Jianhua Wu, et al.
Published: (2024)